209 related articles for article (PubMed ID: 14508868)
1. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.
Karnon J
Health Econ; 2003 Oct; 12(10):837-48. PubMed ID: 14508868
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
[TBL] [Abstract][Full Text] [Related]
4. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
5. Decision analysis of tamoxifen for the prevention of invasive breast cancer.
Grann VR; Sundararajan V; Jacobson JS; Whang W; Heitjan DF; Antman KH; Neugut AI
Cancer J; 2000; 6(3):169-78. PubMed ID: 10882333
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
7. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
8. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
9. Modelling in the economic evaluation of health care: selecting the appropriate approach.
Barton P; Bryan S; Robinson S
J Health Serv Res Policy; 2004 Apr; 9(2):110-8. PubMed ID: 15099459
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
[TBL] [Abstract][Full Text] [Related]
11. Decision-analytical modelling in health-care economic evaluations.
Sun X; Faunce T
Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332
[TBL] [Abstract][Full Text] [Related]
12. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
13. Selecting a decision model for economic evaluation: a case study and review.
Karnon J; Brown J
Health Care Manag Sci; 1998 Oct; 1(2):133-40. PubMed ID: 10916592
[TBL] [Abstract][Full Text] [Related]
14. [Decision analytic modeling and their impact on health care decision making].
Inotai A; Kaló Z; Mészáros A
Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
[TBL] [Abstract][Full Text] [Related]
15. [Decision analysis in radiology using Markov models].
Golder W
Rofo; 2000 Jan; 172(1):80-5. PubMed ID: 10719468
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
17. An introduction to the methods of cost-effectiveness analysis.
Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
[TBL] [Abstract][Full Text] [Related]
18. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
19. [Disease modelling in diabetes mellitus].
Schramm W; Schöffski O; Görtz A; Liebl A
Dtsch Med Wochenschr; 2004 Oct; 129(43):2305-10. PubMed ID: 15483770
[TBL] [Abstract][Full Text] [Related]
20. Emerging methods in economic modeling of imaging costs and outcomes a short report on discrete event simulation.
Hollingworth W; Spackman DE
Acad Radiol; 2007 Apr; 14(4):406-10. PubMed ID: 17368208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
